Go to forum

Studies / Regulation

The FDA’s 2026 peptide compounding changes, explained

BPC-157, TB-500, and ten other peptides came off the FDA’s restricted list, and an advisory panel backed six for compounding. Here is what actually changed and what hasn’t.

Published

Summaries of published research for educational discussion. Not medical advice.

2026 has been the busiest year for peptide regulation in a long time. The FDA reversed a 2023 decision that had effectively stopped pharmacies from compounding BPC-157 and a dozen other popular peptides, and an advisory committee then voted to recommend six of them for compounding. A lot of the coverage has blurred what actually changed. Here is the sequence, and what it does and doesn’t mean.

Background: how compounding is regulated

Compounding pharmacies make customized medications for individual patients with a prescription. Under section 503A of federal law, they can only build those medications from bulk ingredients that meet certain conditions. One route is the 503A bulks list, a list of approved ingredients set through formal FDA rulemaking.

While that list is being built, the FDA sorts nominated ingredients into interim categories:

  • Category 1: under evaluation, and the FDA generally doesn’t object to compounding with them in the meantime.
  • Category 2: raise significant safety concerns. Compounding with these effectively stops.

In 2023, the FDA moved BPC-157 and several other popular peptides into Category 2, citing limited human safety data and concerns about impurities and immune reactions. That’s what pushed many of them out of telehealth and clinic offerings.

What happened in 2026

April: 12 peptides removed from Category 2. In mid-April the FDA said it would take 12 peptides off the Category 2 list: BPC-157, TB-500 (a thymosin beta-4 fragment), KPV, MOTS-c, Semax, Epitalon, emideltide (DSIP), GHK-Cu for injection, Melanotan II, LL-37, dihexa, and PEG-MGF.

The important detail: removal from Category 2 didn’t put them in Category 1. The FDA said directly that removal does not make these ingredients eligible for compounding. They moved out of the “significant safety concerns” bucket without entering the “okay in the meantime” one.

July: the advisory committee votes. On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee considered whether seven of these peptides should be added to the 503A bulks list. FDA staff recommended against all seven, pointing to thin human evidence, poorly characterized substances, and concerns about purity and immune reactions. For BPC-157 specifically, staff noted three adverse event reports, including injection-site reactions and shortness of breath, though it couldn’t be shown the peptide caused them.

The committee went the other way on six of the seven:

  • BPC-157, KPV, and TB-500: recommended, 8 to 6 with one abstention.
  • MOTS-c: recommended, 7 to 5 with two abstentions.
  • Semax and Epitalon: recommended by narrow margins.
  • Emideltide (DSIP): not recommended, 7 to 6 with one abstention.

The meeting drew controversy over newly appointed committee members and possible conflicts of interest, against a backdrop of public enthusiasm for peptides from HHS Secretary Robert F. Kennedy Jr.

What it means now

  • The votes aren’t binding. The committee advises; the FDA decides.
  • Nothing is on the bulks list yet. Adding a substance takes a proposed rule, a public comment period, and a final rule. There’s no deadline, and the FDA has taken more than two years for this step before.
  • Pharmacy compounding of these peptides still isn’t clearly allowed while that process plays out, unless the FDA issues new interim guidance.
  • None of these peptides is an approved drug. Compounding access, if it comes, isn’t FDA approval, and products sold online as “research use only” remain outside this system entirely.
  • Sports rules are separate. BPC-157 and TB-500 remain on anti-doping prohibited lists regardless of FDA decisions.

What to watch for

The next concrete step would be a proposed rule in the Federal Register adding some or all six peptides to the 503A bulks list, or an FDA interim policy allowing compounding while rulemaking continues. Members discuss each development on the forum as it happens.

Sources